By Amina Niasse NEW YORK (Reuters) -President Donald Trump on Monday delivered a blow to the private-sector middlemen who negotiate U.S. drug prices in his executive order on drug pricing, saying he would cut them out as part of a goal to bring the U.S. in line with other countries. The news drove their shares down even as pharmaceutical stocks rose in investor relief about the broad order. "We're going to cut out the middlemen and facilitate the direct sale of drugs at the most favored nation price, directly to the American citizen," Trump said during a press conference. The U.S. pays about three times more than other nations for drugs, and Trump's wide-reaching executive order directs pharmaceutical companies to charge similar prices in the U.S. and Europe. The order says its health department will establish a mechanism for patients to buy more drugs directly from manufacturers. Shares of CVS Health, UnitedHealth Group and Cigna fell 5%, 0.5% and 6%, respectively. The companies individually operate pharmacy benefit managers Caremark, Optum Rx and Express Scripts. Pharmacy benefit managers have already been under regulatory pressure from the Federal Trade Commission, which had sued them under the Biden administration over their insulin pricing practices. The pharmaceutical industry has blamed them for high prices, saying the aftermarket discounts and fees add hidden costs to drug prices. Jeff Jonas, portfolio manager at Gabelli Funds, said the executive order would keep that negative pressure on companies like Cigna, CVS, and UnitedHealth. "The system of high list prices and big, hidden rebates makes the system very opaque and hard to navigate," he said. A spokesperson for CVS said the company welcomed the president’s focus on pricing by pharmaceutical companies and aimed to have discussions with the administration on making pricing more affordable. He said that its negotiations with drugmakers in health plans it operates for Medicare prescription drug insurance had resulted in "significantly lower" costs than that which the government had been able to extract in the 7 of ten drugs it has directly negotiated under the Inflation Reduction Act. Cigna and UnitedHealth did not immediately respond to a Reuters request for comment. Industry spokesman Greg Lopes, vice president of public affairs at the Pharmaceutical Care Management Association, said the problem was with the drugmakers and that PBMs were the only check against drug companies’ unlimited pricing power. American reliance on employer-sponsored health plans poses a challenge to the implementation and may require congressional oversight to enforce, one analyst said. Story Continues Because pharmacy benefit managers provide bundled services to clients, companies could raise the costs of other services or administrative fees, effectively maintaining the same plan pricing, said Julie Utterback, an analyst at Morningstar. She said UnitedHealth shares had not fallen as much because the company is more diversified than Cigna and CVS, which also has a retail pharmacy that could be negatively impacted by lower drug prices. (Reporting by Amina Niasse in New York; Additional reporting by Sriparna Roy in Bengaluru; editing by Caroline Humer and Rosalba O'Brien) View Comments
Trump's drug pricing order delivers blow to pharmacy benefit managers
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...